Expression of Transgenes Targeted to the Gt(ROSA)26Sor Locus Is Orientation Dependent by Strathdee, Douglas et al.
Expression of Transgenes Targeted to the Gt(ROSA)26Sor
Locus Is Orientation Dependent
Douglas Strathdee
1,2*, Helen Ibbotson
2, Seth G. N. Grant
1,2
1The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 2Centre for Neuroscience Research,
University of Edinburgh, Edinburgh, Scotland
Background. Targeting transgenes to a chosen location in the genome has a number of advantages. A single copy of the DNA
construct can be inserted by targeting into regions of chromatin that allow the desired developmental and tissue-specific
expression of the transgene. Methodology. In order to develop a reliable system for reproducibly expressing trangenes it
was decided to insert constructs at the Gt(ROSA)26Sor locus. A cytomegalovirus (CMV) promoter was used to drive expression
of the Tetracycline (tet) transcriptional activator, rtTA2
s-M2, and test the effectiveness of using the ROSA26 locus to allow
transgene expression. The tet operator construct was inserted into one allele of ROSA26 and a tet responder construct
controlling expression of EGFP was inserted into the other allele. Conclusions. Expression of the targeted transgenes
was shown to be affected by both the presence of selectable marker cassettes and by the orientation of the transgenes
with respect to the endogenous ROSA26 promoter. These results suggest that transcriptional interference from the
endogenous gene promoter or from promoters in the selectable marker cassettes may be affecting transgene expression
at the locus. Additionally we have been able to determine the optimal orientation for transgene expression at the ROSA26
locus.
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INTRODUCTION
Spatial and temporal control of gene expression represents an
extremely powerful tool for the analysis of gene function and the
events underlying complex biological processes such as embryonic
development and cognitive function [1,2].
One method of reversibly controlling gene activity is to
regulate its transcription [3]. The transcription control system
based on elements of the tetracycline (tet) resistance operon of E.
coli have been widely used to control gene expression in
mammalian cells. One of the key components of the tet system
is the tetracycline-controlled transactivator (tTA), a fusion protein
between the repressor of the Tn10 tet resistance operon of
Escherichia coli and a C-terminal portion of VP16 that contains
domains capable of activating transcription [4]. tTA will activate
transcription from a suitably engineered minimal promoter by
binding to an array of tet operator sequences positioned
upstream. Random mutagenesis of TetR generated a new
transactivator (rtTA), which binds and transactivates gene
expression in the presence of doxycycline (dox) [5]. Improved
versions of rtTA have been developed to give tighter gene
expression, increased sensitivity towards the inducer, enhanced
stability and expression in mammalian cells, and more uniform
transgene expression in the induced cells [6–8].
Introduced transgenes are frequently susceptible to gene
silencing [9]. Although the mechanism for this process is poorly
understood, both the integration site and the variable copy
number at the integration site can influence the expression level
[9–11]. This is often seen as progressive silencing of gene
expression initially resulting in mosaic expression levels and often
resulting in complete shutdown of transgene expression [12].
As randomly integrated transgenes are susceptible to gene
silencing, targeting transgenes to a chosen location in the mouse
genome has a number of advantages [13,14]. Firstly the
integration site can be chosen to allow insertion of the transgene
into a region of chromatin favourable for expression and that
avoids an undesirable insertional mutagenesis. Additionally only
a single copy is be introduced which avoids problems associated
with a large multicopy array.
The Gt(ROSA)26Sor locus (ROSA26) was first described as
a gene trap which is ubiquitously expressed in mouse embryos
[15]. As the ROSA26 locus is active in most cells any promoter
inserted into the locus should not be restricted in its expression by
unfavourable chromatin configurations. This locus has been
widely used for expressing endogenous sequences, often reporter
genes usually from the endogenous promoter [16,17]. The
promoter from the ROSA26 locus has been used to drive
widespread expression of marker genes in transgenic rats and
mice [18]. The ROSA26 promoter has also been used to express
the tTA and rtTA successfully [19–21]. Other studies have shown
that targeting tissue-specific promoters, including BAC sequences,
to specific genomic locations leads to its expression in the
appropriate tissue and cell-specific pattern [22–26].
In order to test if the ROSA26 locus was and if the local
chromatin structure would effect transgene expression at the locus
constructs expressing the rtTA and a reporter gene downstream of
the tetracycline-responsive element (TRE) were targeted into
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PLoS ONE | www.plosone.org 1 December 2006 | Issue 1 | e4ROSA26 locus in both orientations. Expression was found to be
dependent on both the orientation of the transgene and the
presence of an adjacent selectable marker.
RESULTS
Targeting strategy for introducing to ROSA26 locus.
Establishing dox-dependent gene expression requires two different
transgenes, an activator and a responder transgene. Activator
constructs were generated with a CMV promoter driving the
rtTA2
s-M2 variant of the tetracycline transcriptional activator.
The CMV promoter was chosen as it works inefficiently in ES cells
and should be sensitive to position effects [27]. The cassette was
cloned into the targeting vector in both orientations to produce the
A1 and A2 targeting constructs (Figure 1A). The responder
construct contained an EGFP transgene under control of the
tetracycline responder element. This again was cloned into the
targeting vector in both orientations to produce the B1 and B2
targeting vectors.
Cell lines were generated by sequentially targeting HM1 ES
cells with first the activator and then the responder construct.
Clones of cells which had been electroporated with the activator
targeting vectors were isolated by selection with G418. Correctly
targeted cells were initially identified by PCR and subsequently
confirmed by Southern blot (Figure 1B). Cell lines which had the
activator transgene correctly inserted at the ROSA26 locus were
then electroporated with the responder transgene and selected on
puromycin and G418. Resistant colonies were then analysed for
correct targeting of the responder transgene to the ROSA26 locus.
Consequently four different cell lines were generated with the
activator and responder transgenes in both orientations
(Figure 1C).
Figure 1. Targeting strategy for introducing to ROSA26locus. (A). Diagram of targeting constructs to introduce Dox responsive transgenes into locus.
A1 and A2 introduce the same activator transgene in opposite orientations. B1 and B2 introduce the same responder transgene in opposite
orientations. (B) Four different cell lines were produced with the activator and responder transgenes in different orientations (C) Southern blots
probed with 59 and 39 flanking probes produce the correct band sizes to demonstrate appropriate targeting of constructs.
doi:10.1371/journal.pone.0000004.g001
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at the ROSA26 locus.
After targeting both the activator and responder constructs to the
ROSA26 locus, EGFP expression was induced by treating the cells
with doxycycline. No fluorescence was detected above background
in single targeted cells, containing either the activator construct or
responder construct alone (Figure 2B). This demonstrates that the
responder construct has very low background activity when
targeted into the ROSA26 locus.
Before addition of dox to the A1B1 double targeted cells
containing both transgenes there again was no fluorescence
detectable above background (Figure 2A and 2B). This demon-
strates that there is very little leaky expression when both
constructs are targeted to different alleles of the ROSA26 locus.
Upon addition of dox to the medium, robust fluorescence was
detected in the double targeted cells. This demonstrates that both
transgenes are functioning appropriately when targeted to separate
alleles of the locus. Furthermore EGFP expression induced by the
activator transgene follows a similar dose response curve to that
previously published (Figure 2C).
Transgene expression level at ROSA26 is consistent
between clones and dependent on transgene
orientation.
In order to test if the expression levels of the transgenes were
influenced by the regulatory sequences at the ROSA26 locus both
the activator (A) and responder (B) constructs were introduced into
the locus in both orientations. Four double targeted cell lines were
generated with different combinations of the two transgenes
(Figure 1C).
Examples of the induction of EGFP expression in the A1B1 and
A2B2 cell lines are shown (Figures 3A and 3B). Before
administration of dox to the cells, none of the four cell lines
showed any significant levels of EGFP expression (Figures 3B and
3C). This supports the conclusion that the level of background
activity of the constructs is very low and that targeting the
Figure 2. Dox regulated gene expression works appropriately at the ROSA26 locus. (A) EGFP expression induced in A1B1 cells by addition of dox to
a final concentration of 1 mgml
21.( i) and (iii) Phase contrast. (ii) and (iv) EGFP fluorescence (B) EGFP expression in single targeted and double
targeted cell lines in reponse to 1 mgml
21 dox. Induction of EGFP is only seen in the A1B1 cells (F(2,30)=1167.61, p,0.0001). Each point is an average
of three measurements each from two independently targeted cell lines. Error bars denote standard deviations. Asterisks indicate statistically
significant differences. (C) Dose response curve EGFP expression in A1B1 cells in response to dox.
doi:10.1371/journal.pone.0000004.g002
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significant levels of background EGFP expression.
After administration of dox all four cell lines showed robust
expression of EGFP (Figures 3B and 3C). When the expression
was quantitated though, it was obvious that the transgenes that
were in the opposite orientation to the ROSA26 promoter showed
higher expression than those which were in the same orientation as
the ROSA26 promoter (Figure 3C). This effect was more
pronounced for the activator transgene than the responder
transgene. The difference in level of induced EGFP expression
correlated well with the difference in the level of expression of the
rtTA transgene when measured by RT-PCR (Figure 3D). This
suggests that the difference in the expression level between the
different cell lines is mainly attributable to the level of rtTA
expression driven by the CMV promoter.
The expression levels in at least two independently targeted cell
lines were measured for each of the orientations described above.
When the expression levels in these cell lines are averaged
independently, the genetically identical cell lines vary by about 10–
15% in induced expression of EGFP (data not shown).
Expression level can be increased when selectable
marker is removed.
In order to test if the expression level was influenced by the
sequences present in the selectable marker cassette, it was removed
Figure 3. Expression level is dependent on orientation. (A) Diagram of orientation of constructs in cell lines. (B) A1B1 and A2B2 cells induced with
doxycycline (i) A1B1 phase contrast (ii) A1B1 EGFP expression (iii) A2B2 phase contrast (iv) A2B2 EGFP expression (C) Graph of expression levels in
induced and uninduced cell lines quantitated by fluorimetry. A2 cell lines have higher EGFP expression compared with the A1 cell lines
(F(1,40)=346.09, p,0.0001). Expression levels between the B1 and B2 cell lines were not significantly different (F(1,40)=0.05, p=0.8211). Each point
is an average of three measurements each from two independently targeted cell lines. Error bars denote standard deviations. Asterisks indicate
statistically significant differences. (D) Expression level of rtTA measured by RT-PCR.
doi:10.1371/journal.pone.0000004.g003
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the marker gene removes the thymidine kinase expression cassette
(Figure 4A). Cells were transiently transfected with a Cre
expression plasmid and selected with gancyclovir. After selection
in gancyclovir, resistant cell lines were analysed by PCR to ensure
the selectable marker had been removed. More than 90% of the
colonies recovered had undergone the appropriate recombination
to remove the selectable marker (data not shown).
Resistant colonies were then analysed for EGFP expression by
administration with doxycycline. For the cell lines A2B1D and
A2B2D, with the selectable marker cassette removed, robust
expression of EGFP was induced by addition of dox (Figure 4B).
The expression in these cell lines is significantly higher than the
expression of the cell lines before removal of the selectable marker
(Figure 4C). This suggests that the sequences in the selectable
marker had been affecting the expression of the EGFP. When
these sequences are removed the EGFP expression level is
increased.
Expression level is decreased when selectable
marker is removed and promoter is in same
orientation as ROSA26 promoter.
The selection marker was removed from the A1B1 and A1B2 cell
lines by transient transfection of Cre recombinase and selection of
the cells on gancyclovir (Figure 5A). Resistant cell lines were
analysed by PCR to ensure that the selectable marker gene had
been removed (data not shown).
Administration of dox to these cell lines again lead to a robust
increase in the expression of EGFP (Figure 5B). However the
expression level induced in the A1B1D and A1B2D cell lines
without the selectable marker was lower than the cell lines. In this
Figure 4. Expression level can be increased when selectable marker is removed. (A) Diagram of orientation of constructs in cell lines. (B) A2B2 and
A2B2D cells induced with doxycycline (i) A2B2 phase contrast (ii) A2B2 EGFP expression (iii) A2B2D phase contrast (iv) A2B2D EGFP expression (C)
Graph of expression levels in induced and uninduced cell lines quantitated by fluorimetry. Expression of EGFP is higher when these cell lines have lost
the selectable marker cassette (F(1,40)=77.25, p,0.0001). The orientation of the TRE EGFP makes no difference to expression level (F(1,40)=1.14,
p=0.2910). Each point is an average of three measurements each from two independently targeted cell lines. Error bars denote standard deviations.
Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0000004.g004
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the CMV promoter from the effects of the endogenous ROSA26
promoter.
DISCUSSION
The ROSA26 locus is widely used as a locus for expressing
transgene sequences. The data in this paper suggest that the
sequences at the ROSA26 locus may have a significant effect of
expression of sequences targeted to the locus. Transgene
expression was seen to be highly dependent on orientation when
inserted into the ROSA26 locus. The expression level is lower
when the transgene is adjacent to, and in the same orientation as,
the endogenous promoter. It seems likely that this may be caused
by transcriptional interference with the endogenous ROSA26
promoter.
A recent report showed that the b-globin locus control region
can silence as well as activate gene expression [28]. This silencing
was shown to occur by transcriptional interference and was
dependent on the orientation of the introduced transgene. This is
a similar effect on gene expression as that observed here and it
seems likely that a similar effect may be causing the orientation
dependent transgene expression at the ROSA26 locus. Transcrip-
tional interference has been proposed to influence gene expression
on a genome wide basis [29]. And it has also been demonstrated
that two transgenes will interfere with each other when targeted
into the same locus [30]. This interference is more pronounced
when the transgenes are arranged in the same orientation, similar
to the arrangement of the A1 transactivator construct and the
endogenous ROSA26 promoter. The A1 activator construct shows
a lower level of expression than A2 (Figure 3C and D).
Figure 5. Expression level is decreased when selectable marker is removed and promoter is in same orientation as ROSA26 promoter. (A) Diagram of
orientation of constructs in cell lines. (B) A1B1 and A1B1D cells induced with doxycycline (i) A1B1 phase contrast (ii) A1B1 EGFP expression (iii)
A1B1D phase contrast (iv) A1B1D EGFP expression (C) Graph of expression levels in induced and uninduced cell lines quantitated by fluorimetry.
Expression of EGFP is lower when the selectable marker is removed from the A1 cell lines (F(1,40)=51.77, p,0.001). Again the orientation of the TRE-
EGFP makes no significant difference to the expression levels observed (F(1,40)=0.05, p=0.8295). Each point is an average of three measurements
each from two independently targeted cell lines. Error bars denote standard deviations. Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0000004.g005
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endogenous ROSA26 promoter and the introduced CMV
promoter seemed to enhance this effect. The A1B1D cell lines
show higher expression that the A1B1 cells (Figure 5C). Removing
the selectable marker, including both the HSV-tk and PGK-neo
genes, brings the CMV promoter much closer to the endogenous
promoter. This again implies that the reduced expression is
dependent on the activity of the endogenous promoter and
suggests that in this case the selectable marker may be partly acting
as an insulator to reduce the effect of the ROSA26 promoter on
transgene expression [31]. It has been found that suppression of
downstream expression in tandem constructs is relieved when
a polyadenylation and pause site separate the genes [32]. As the
selectable marker contains two genes with polyadenylation sites
this may explain why it acts as an insulator sequence in this case.
On the other hand removing the selectable marker when the
CMV promoter is in the opposite orientation to the ROSA26
promoter enhances EGFP expression levels. The A2B2D cell lines
show higher expression than the A2B2 cells (Figure 4C). This may
be because the HSV-tk and PGK-neo genes in the selectable
marker are interfering with the expression of the transgene and
when removed this expression level is increased. It has been
observed that insertion of a transgenic selectable marker to make
a gene knockout can influence the expression of neighbouring
genes [33]. Often dramatically different phenotypes can be
observed in the presence and absence of a selectable marker. In
this case removing the marker enhances the expression of the
remaining A2 activator transgene.
The expression of EGFP is dependent on the expression of both
the activator and responder constructs. The orientation of the
activator transgene has a more significant effect on EGFP
expression than the orientation of the responder. For example,
the difference between the EGFP expression in the A2B2 and
A1B2 is greater than the difference between the A1B1 and A1B2
(Figure 3B). Activation of EGFP expression must be more reliant
on the level of the rtTA present in the cells prior to administration
of dox. There is still a small effect of the orientation of the
responder transgene.
It is not clear why the effect is more pronounced on the
activator than the responder. It is possible that upon DNA binding
in response to dox, the VP16 activation domain of the rtTA is
strong enough to overcome local effects of the integration site.
Hence EGFP levels which result from a combination of the
expression of both transgenes, appear to depend more on the level
of activity of the CMV promoter than the orientation of the of the
responder element. The VP16 activation domain has been shown
to be a potent transcriptional activator that can interact with many
proteins, including transcription factors and chromatin-modifying
co-activators, and can overcome the repressive effects of
heterochromatin [34–36].
It is impossible to rule out that removing the selectable marker
cassette leads to an increase in expression levels of the rtTA which
is toxic to the cell. Substantial overexpression of the VP16
activator has been shown to be toxic to cells [37,38]. However as
the reverse orientation activates EGFP expression more efficiently
and shows higher rtTA RNA expression levels, this possibility
seems unlikely.
When the average expression levels of genetically identical
clones are compared (e.g. two A2B2 cell lines), the variation
between the cell lines is approximately 10–15%. This is not much
higher than the variation between replicate expression level
measurements of the same cell line. This suggests that targeting
transgenes to the ROSA26 locus allows repeatable and reliable
expression of inserted sequences.
It would be of interest to determine whether the changes in
expression levels observed are due to changes in mosaic
expression. Although there is variation in expression level between
different cells, the majority of the undifferentiated ES cells express
at least a small amount of the EGFP in all the cell lines examined.
It seems more likely that the differences between cell lines are due
to a change in expression levels within cells rather than a change in
the proportion of cells which express the transgenes. A similar
effect has been observed on the CMV promoter driven EGFP
transgene in 293 cells. silencing of the transgene occurred by
a reduction of expression levels rather that a decrease in the
proportion of expressing cells [39]. This effect could be analysed in
more detail by fluorescent activated cell sorting of the clones. Any
analysis of this sort could be complicated by the fact there are
likely to be different levels of differentiated cells in embryonic stem
cell cultures and differentiated cells are likely to inactivate the
CMV promoter [40].
The orientation dependent expression at the ROSA26 locus
may have profound effects on expression on ES cells but also may
effect expression in transgenic mice. Transcriptional interference
has been proposed as a mechanism for transgene silencing [31]. It
is possible therefore that although transcriptional interference does
not completely silence transgene expression in ES cells that the
difference in expression may be more dramatic in adult mouse
tissues derived from the ES cells.
It may be possible that these effects could be avoided if the
transgene was targeted upstream of the ROSA26 promoter.
Indeed a similar strategy has been used to target exogenous
sequences to the HPRT locus [14,21–23]. In this case the
expression level and pattern of the transgenes was not dependent
on the orientation of the inserted sequences. However as the
HPRT locus is on the X chromosome it will be randomly
inactivated in female mice, which may not be ideal for every
experiment.
This study has allowed us to define an optimal orientation for
the introduction of exogenous promoters and transgene sequences
into ROSA26. Targeting transgenes to a region of the genome,
which allows optimal expression, will allow be significantly more
efficient than the conventional pronuclear microinjection ap-
proach for introducing a large number of transgene constructs. As
expression levels are unpredictable following pronuclear microin-
jection, multiple transgenic lines must be generated bred and
analysed for expression. Targeting transgenes to a defined
genomic region circumvents the necessity for multiple lines to be
analysed for expression. This approach is therefore much more
easily scalable that the conventional approach. The CMV
promoter was used in the initial set of experiments as it sensitive
to position effects in ES cells and although the results described
apply only to this promoter, work is currently underway to test
a range of neuron specific promoters to determine how efficiently
these work when targeted to the ROSA26 locus.
Overall these results suggest that although targeting transgenes
is an extremely useful tool in overcoming the gene silencing effects
associated with the conventional transgenic approach, care must
be take to avoid any adverse effect of the local chromatin structure
and endogenous gene sequences on the inserted transgene.
MATERIALS AND METHODS
Vector construction
Activator constructs were generated by cloning the CMV-rtTA-
SV40 late polyA fragment from pUHrT62-1 [8] and the selectable
marker from pLTNL [41], which includes both the PGK-neo and
HSV-tk resistance genes flanked by loxP sites, were cloned into
Transgene Expression at ROSA26
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EGFP fused to tau into a modified pTRE2Hyg (Clontech) and the
fragment containing the tet operator and EGFP was subcloned
into pROSA26-1 along with the selectable marker from pLTNL in
which the PGK-Neo resistance gene had been swapped for an
SV40-Puro-SV40 polyA derived from pPUR (Clontech). For
electorporation 100 mg of plasmid DNA was linearised by
digestion with SwaI and ethanol precipitated before resuspension
in HBS.
Embryonic stem cell culture
ES cells were maintained without feeders in Glasgow’s modifica-
tion of Eagle’s medium (Invitrogen) supplemented with 400 U/ml
recombinant murine leukaemia inhibitory factor (LIF; Chemicon),
0.1 mM MEM non-essential amino acids (Invitrogen), 10% foetal
bovine serum Stem Cell Technologies) and 0.1 mM 2-mercap-
toethanol (Sigma). HM-1 ES cells [42] were electroporated by
mixing 1 x 10
7 cells with 100 mg of linearised DNA (targeting
experiments) in 0.8 ml of HEPES-buffered saline (pH 7.5), giving
a single pulse at 800 V, 3 mF (Bio-Rad gene pulser) and plating at
1x1 0
6 cells/10 cm dish. Selection was applied 20–24 h after
electroporation. Cells were selected in either G418 (300 mgml
21),
puromycin (1 mgml
21) or gancyclovir (1 mgml
21). EGFP was
induced by addition of doxycycline usually (1 mgml
21) to normal
growth medium.
DNA analysis
Cells were lysed and DNA extracted by standard methods. Initial
genotyping and screening for loss of the selectable marker was
performed by PCR using Expand HiFi (Roche) according to the
manufacturer’s recommendations. Primers used for genotyping
targeted ES cells were 59 CGCCTAAAGAAGAGGCTGTG and
39 GCCTGAAGAACGAGATCAGC. For screening for loss of
selectable marker a different 39 primer for each transgene was used
in combination with the 59 genotyping primer. (A1, GAGC-
GAGTTTCCTTGTCGTC; A2, ACGCTATCTGTGC-
CAAGGTCC; B1, TCCCGGTGTCTTCTATGGAG; B2,
CCCAGTCATAGCTGTCCCTC)
For Southern blotting after EcoRI digestion, DNA was
electrophoresed through 0.8% agarose and transferred onto
Zetaprobe according to the manufacturer’s recommendations
(Bio-Rad). Hybridisation was performed at 65uC. Probes were
labelled by random hexamer labelling (Rediprime II, Amersham)
according to the manufacture’s instructions. The final wash was
with 0.1XSSC, 0.1% SDS at 65uC. Probes for the locus were
isolated by PCR from wild-type genomic DNA using the folloing
primers using standard conditions (59 probe: TGGAGTAGG-
CAATACCCAGG and CACAGCCTCTTCTTTAGGCG, 39
probe: GGCACTGTTCATTTGTGGTG and GTGCCTGT-
GGAGGCTAGAAG)
For reverse-transcriptase PCR (RT-PCR), total RNA was
isolated from ES cell cultures using Qiagen RNeasy Mini Kit
according to the manufacturer’s instructions. First strand cDNA
was made from RNA, using oligo dT primers, with RETROscript
(Ambion Inc.) PCR was then performed on the cDNA using
standard conditions with primers for rtTA2
s-M2 (59
CTGTGTCAGCAAGGCTTCTC and 39 TCAGCAGGCAG-
CATATCAAG)
Fluorimetry
EGFP expression was quantitated by fluorimetry as described by
Yata et al. [43]. Briefly cells were harvested and homogenized in
phosphate-buffered saline containing 0.5% Triton X100,
10 mgml
21 leupeptin, 20 mgml
21 aprotinin, and 0.1 mM phenyl-
methyl sulfonyl fluoride (PMSF). Homogenates were centrifuged
in a microcentrifuge for 20 minutes, the supernatants collected,
and protein concentrations determined using a protein assay
reagent (BioRad).GFP fluorescence was assessed with a fluorometer
(Turner Biosystems). Relative fluorescence units per mg of protein
are shown on the graphs. Each point is an average of three
measurements each from two independently targeted cell lines.
Error bars denote the standard deviation calculated from these six
measurements. Between-measures ANOVAs were conducted
using Statview 5.0.1, as appropriate.
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